SUBSTANCE
STATUS DATE CLINICAL INDICATIONS
AND DESCRIPTIONS
Sermorelin
FDA approved and discontinued
July, 2008
IN SEPTEMBER 1997, SERMORELIN WAS APPROVED FOR THE TREATMENT OF GROWTH HORMONE DEFICIENCY IN CHILDREN
Examorelin
Interrupted
Tabimorelin
Interrupted
AT
IT SEEMS INTERRUPTED.
Pralmorelin (i.v.)
Approved in Japan
October, 2004
DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS AND CHILDREN (> 4 YEARS).
Ipamorelin
Interrupted
Ulimorelin
Active
March, 2017
EVALUATING THE EFFECT OF ULIMORELIN IN PATIENTS WITH INTOLERANCE OF ENTERAL FEEDING
Relamorelin
Currently evaluated by the FDA
October, 2016
TREATMENT OF DIABETIC GASTROPARESIS.
TZP-102
Active
2013
FDA GIVES TZP-102 A QUICK DESIGNATION FOR TREATMENT OF DIABETIC GASTROPARESIS IN 2009.
Tesamorelin
FDA approved
November, 2010
REDUCTION OF EXCESS ABDOMINAL FAT IN HIV INFECTED
PATIENTS WITH LIPODYSTROPHY.
Capromorelin (oral)
FDA approved
June, 2016
APPETITE STIMULATION IN DOGS WITH DECREASED APPETITE.
Anamorelin
Requested for approval at EMA
November, 2015
CACHEXIA ASSOCIATED WITH NSCLC.
Macimorelin
Requested for FDA approval
February, 2017
DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS.